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KESAN PENGGUNAAN SEMBURAN MADU KE ATAS KERADANGAN, 
REGENERASI DAN BAIK PULIH EPITELIA SALURAN PERNAFASAN 
PADA MODEL ARNAB YANG MENGALAMI KECEDERAAN PEPARU 
KRONIK DIAKIBATKAN OLEH OVALBUMIN 
ABSTRAK 
Selama beberapa dekad, penyakit kecederaan peparu kronik telah 
mengakibatkan ribuan kematian di seluruh dunia. Penyakit ini terjadi apabila saluran 
pernafasan mengalami perubahan dari segi struktur dan komponen-komponen sel di 
sekelilingnya. Penyakit ini tidak boleh disembuhkan, namun begitu, pelbagai jenis 
rawatan telah tersedia untuk membantu mengurangkan gejala-gejala penyakit dan 
seterusnya menghalang penyakit ini daripada bertambah serius. Di peringkat klinikal, 
terapi berasaskan ubat-ubatan telah diperkenalkan untuk membantu mengurangkan 
gejala serangan penyakit ini. Walau bagaimanapun, usaha bagi mengenalpasti 
rawatan alternatif bagi penyakit ini berasaskan bahan-bahan semulajadi masih 
diteruskan dengan tujuan untuk mengurangkan kesan-kesan sampingan akibat 
penggunaan terapi ubat-ubatan. Objektif umum bagi kajian ini adalah untuk 
mengenalpasti kesan rawatan semburan madu ke atas pembaikpulihan dan regenerasi 
sel-sel epitelia saluran pernafasan pada model arnab yang mengalami kecederaan 
peparu kronik diakibatkan oleh ovalbumin. Model arnab telah diberikan kecederaan 
melalui suntikan ovalbumin, dan seterusnya rawatan semburan madu Tualang telah 
diberikan menggunakan penebula. Model rawatan telah dibahagikan kepada dua 
kumpulan iaitu untuk mengenalpasti kemampuan madu Tualang untuk bertindak 
sebagai agen penyelamat dengan cara memberi rawatan kelegaan segera atau sebagai 
xv 
 
agen penghalang (untuk mengelakkan kecederaan berulang). Kajian ini telah 
dilakukan menggunakan dua kepekatan madu Tualang (Koompassia Excelsa) yang 
berbeza; 25% dan 50%. Kajian ini memfokuskan kesan histologi rawatan semburan 
madu terhadap tiga parameter kecederaan peparu kronik iaitu; (1) membaikpulih 
struktur saluran pernafasan, (2) mengurangkan bilangan dan/atau menyingkirkan sel-
sel goblet, dan (3) mengurangkan kemasukan sel-sel keradangan ke dalam saluran 
pernafasan.   Rawatan semburan madu ini (tanpa membezakan kepekatan madu yang 
digunakan dan mod rawatan) memberi keputusan yang memberansangkan apabila 
ianya mampu mengurangkan gejala-gejala penyakit ini dengan mengembalikan 
semula struktur saluran pernafasan, mengurangkan bilangan sel-sel goblet dan 
mengurangkan kemasukan sel-sel eosinofil ke dalam bahagian tisu peparu. Dapatan 
daripada kajian ini menunjukkan rawatan semburan madu boleh bertindak sama ada 
sebagai agen penyelamat dan juga agen penghalang; dan seterusnya mempunyai 
potensi untuk digunakan sebagai rawatan alternatif bagi penyakit kecederaan peparu 
kronik pada masa akan datang.  
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THE EFFECT OF AEROSOLISED-HONEY ON INFLAMMATION, 
REGENERATION AND REPAIR OF AIRWAY EPITHELIA IN RABBIT 
MODEL OF OVALBUMIN-INDUCED CHRONIC LUNG INJURY  
ABSTRACT 
For the past few decades, chronic lung injury has attributed to thousands of 
death worldwide. The disease occurred due to alteration in the structure as well as 
cellular components of the airways which later lead to airway remodelling and 
inflammation. This disease is not curable; however, treatments are available to 
reduce the disease symptoms and preventing the disease progression. At the clinical 
setting, conventional drug therapy is available to lessen disease exacerbations; 
however, there is still a need to find the alternative treatments that incorporated with 
natural resources to minimize the side effect of drug therapy. The general objective 
of this study was to study the effect of aerosolised-honey on airway epithelium repair 
and regeneration following ovalbumin-induced chronic lung injury in rabbit model. 
Injury was first introduced in the rabbit model by ovalbumin sensitization and 
treatment of aerosolised-Tualang honey was given to the animals using a nebuliser. 
Two models had been developed with the aim to investigate the potentiality of 
Tualang honey to serve as rescue agent by providing quick relief upon disease 
symptoms or as preventive agent (to prevent the progression of the disease). 
Research was carried out using two concentrations of Tualang (Koompassia Excelsa) 
honey; 25% and 50%. Current study was focussing on the histological effect of 
aerosolised-honey treatment towards three parameters of chronic lung injury; (1) 
restoration of airway structures, (2) improving and/or eliminating the goblet cell 
hyperplasia, and (3) reducing the inflammatory cells infiltration. Results between the 
xvii 
 
treatment groups, naive and control groups were statistically compared. Aerosolised-
Tualang honey (regardless of any concentration and modes of action) was shown to 
be able to alleviate the disease symptoms by restoring the airway structures, 
eliminating the goblet cell hyperplasia and reducing the eosinophils infiltration. 
These findings provide the evidence that aerosolised-honey can act as both rescue 
and preventive agents, thus it could be useful to be applied as alternative treatment in 
managing the chronic lung injury patients in future.       
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CHAPTER 1 
INTRODUCTION 
1.1  Lung disease 
Lung disease is disease affecting airways and other structures of the lung. It is 
the most common medical complication been reported worldwide and the disease can 
be divided into two categories; acute and chronic. Acute respiratory disease is 
described as the condition of abnormal lung function when exposed to certain stimuli 
and can be developed due to factors such as lung infection, inhalation of highly toxic 
gases, sepsis and others (Kamaruzaman et al., 2013).  
Meanwhile, the development of chronic lung disease is often associated with 
smoke inhalation, genetic and occupational environment (Kamaruzaman et al., 
2013). Chronic lung disease is estimated to affect hundreds of millions of people 
worldwide and examples of these non-communicable disease are asthma, chronic 
obstructive pulmonary disease (COPD), bronchiectasis, bronchitis, emphysema, lung 
cancer and lung fibrosis (World Health Organization, 2007). Disease outcomes are 
including airway inflammation, airway hyperresponsiveness (AHR) and mucus 
overproduction (Kamaruzaman et al., 2013). 
1.2 Chronic lung injury – COPD 
COPD is a major public health problem and listed as the major and fourth 
leading cause of morbidity and mortality in the United Kingdom and United States 
respectively (Rabe et al., 2007, Parmar and Raines, 2015). There are about 16 
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millions of people diagnosed with COPD and most commonly seen in elderly 
patients (Rabe et al., 2007).   
COPD is characterised by poorly reversible airflow limitation with chronic 
inflammation in the lungs that occurred as a result from long terms exposure towards 
noxious particles and gases particularly cigarette smoke. The disease is progressive, 
often develop slowly and the symptoms worsen over time (Rabe et al., 2007).  
The pathological changes of the disease occurred throughout the pulmonary 
zones including proximal cartilaginous airway, peripheral airway, lung parenchyma 
and pulmonary vasculature (Pauwels et al., 2001, MacNee, 2006). The inflammatory 
and airway remodelling increased with disease severity and persist even after 
smoking cessation (MacNee, 2006). As a result, these lead to the accumulation and 
infiltration of inflammatory cells such as macrophages, T lymphocytes 
(predominantly CD8
+
) and neutrophils into airway regions. Soon, this contributes to 
the release of mediators by inflammatory cells such as interleukin-8 (IL-8), tumor 
necrosis factor-α (TNF-α), leukotriene B4 (LTB4) and others, which later resulting in 
damaging of the lung structures and sustaining of neutrophilic inflammation 
(Pauwels et al., 2001, MacNee, 2006). 
The pathophysiologies of COPD including mucus hypersecretion, cilliary 
dysfunction, airflow limitation, pulmonary hyperinflation, gas exchange 
abnormalities and pulmonary hypertension.  
Mucus hypersecretion occurred due to squamous metaplasia, increased in the 
number of goblet cells and increased the size of bronchial submucosal glands in 
response to chronic irritation by noxious particles and gases. As a result, patients 
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with COPD will experience chronic productive cough and sputum production 
(MacNee, 2006).   
Meanwhile, cilliary dysfunction occurred due to squamous metaplasia of 
epithelial cells. As the consequence, this results in abnormal mucocilliary escalator 
and patients will having difficulty in expectorating (MacNee, 2006). 
Chronic inflammation leads to persistent cycles of airway wall repairing and 
later resulted in the structural remodelling of the airway wall. In addition, increasing 
collagen content and scar formation within the airway wall leads to airway lumen 
narrowing and thus producing fixed airway obstruction (Pauwels et al., 2001). This 
condition is worsening by the presence of inflammatory exudates in the small airway 
(less than 2 mm internal diameter) (MacNee, 2006).  
In overall, patients of COPD will experience clinical symptoms like shortness 
of breath, chronic cough and sputum production (Pauwels et al., 2001).     
1.3 Chronic lung injury - asthma 
Asthma is the most common chronic inflammatory airway disease that 
affecting millions of people worldwide. In 2004, it has been reported that about 300 
millions of people globally had asthma with 250,000 annual deaths attributed by the 
disease (Masoli et al., 2004, World Health Organization, 2007). In Malaysia, 
according to the Third National Health and Morbidity Survey (NHMS III) conducted 
in 2006, the prevalence rate of asthma among adults has been reported about 4.5% 
and the rate was estimated to be rising especially in children (Usha Devi et al., 2011). 
In a research focusing on the prevalence of childhood asthma in Selangor, Malaysia, 
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the prevalence rate of asthma among children was reported to be 24% (Surdi Roslan 
et al., 2011). 
In a healthy individual, the process of inhaling and exhaling of air occurred 
freely without any obstruction. However, in individuals with asthma, the muscle 
surrounding the airway became constricted, thus led to difficulty in breathing. This 
was worsening by the inflammation of airway which contributed to breathlessness 
and chest tightness. Asthma is characterized as repetitive disease of the airway thus 
individuals with asthma had been diagnosed to have recurrent episodes of wheezing, 
breathlessness, chest tightness and nocturnal coughing (Kamaruzaman et al., 2014).  
Usually this disease is treated by means of medication. Delay in seeking 
treatment for the disease may lead to serious asthma attack and fatality. For 
asthmatic individuals, it is important to manage the disease with proper management 
which including taking the medication and practicing the healthy lifestyle. Improper 
asthma management may hinder an individual from enjoying the life and increase 
their life burden. According to a global research known as Spring into Action, about 
90% of asthmatic individuals is reported to have difficulty in participating in any 
physical activity and at least 70% of the respondents claimed asthma causing sleep 
disturbance (Aziah, 2014). Improper asthma management may increase the 
individual‟s visit to the emergency department and admittance to the hospital and 
thus, increase their financial burden.     
Asthma is a complex disease and its development process involving both 
central and peripheral airways. There are two major changes that took place in the 
development of asthma; changes in (1) airway structures and (2) cellular (Saetta and 
Turato, 2001).  
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1.3.1 Cellular changes of asthma 
Cellular change is a process involves infiltration of inflammatory cells into the 
airway regions. The pathophysiology of asthma is associated with infiltration of 
inflammatory cells such as eosinophils, mast cells, lymphocytes, macrophages and 
neutrophils (Fahy et al., 2000, Saetta and Turato, 2001, Jang et al., 2012, Shifren et 
al., 2012).  
Previous studies agreed that eosinophilic infiltration is considered as the most 
striking feature for asthma (Fahy et al., 2000). In a review written by Saetta and 
Turato (2001), the article discussed about the distribution of eosinophilic infiltration 
in both airways and its physiological implication. In small airways, eosinophils are 
densely distributed between the smooth muscle and the alveolar attachment of the 
airway wall which later promotes the airway constriction by decreasing the tethering 
effects of parenchyma on the airway wall. Meanwhile in the large airways, 
eosinophils are densely distributed between the smooth muscle and the basement 
membrane. As a result, smooth muscle shortened and later led to decrease in the 
airway calibre, thus promoting the airway constriction (Saetta and Turato, 2001).  
However, in the case of severe asthma, neutrophils seems to be dominant 
compared to eosinophils (Monteseirin, 2009). Findings from various study concluded 
that neutrophilic airway inflammation is more profound in patients of severe asthma 
compared to patients with slight asthma (Wenzel et al., 1997, Just et al., 2002). 
Neutrophils as the first cell recruited to the site of allergic reaction may influence the 
clinical presentation and play a role in development of severe asthma (Monteseirin, 
2009). Neutrophilic inflammation is thought to be involved in the progression of 
persistent airflow limitation in asthma and can lead to sudden death (Shaw et al., 
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2007). This is further supported by finding of increased level of neutrophils in the 
airways and submucous glands from biopsy materials of fatal asthma patients (Sur et 
al., 1993, Carroll et al., 2002).    
1.3.2  Structural changes of asthma 
Asthma is usually associated with alteration in the structure of airway, a 
condition known as airway remodelling, which occurred in conjunction with or 
because of persistent airway inflammation (Tang et al., 2006, Tagaya and Tamaoki, 
2007). Prolonged inflammation leads to alteration in the structure of airway 
epithelium, mucosal and submucosal regions and contributed to thickening of the 
airway wall. As illustrated in Figure 1.1 and Figure 1.2, the structural changes 
observed include epithelial injury including epithelial damage and denudation, goblet 
cell hyperplasia, mucous gland hypertrophy, increased in the smooth muscle (SM) 
mass, subepithelial fibrosis, thickening of the airway mucosal, angiogenesis, and 
enhanced deposition of extracellular matrix (ECM) proteins (Fahy et al., 2000, 
Mauad et al., 2007, Tagaya and Tamaoki, 2007, Girodet et al., 2011). Airway 
remodelling involves both small and large airways as well as surrounding of 
peribronchial areas.       
1.3.2 (a) Epithelial cell alteration 
Airway epithelium serves as a barrier that protects internal milieu of the lungs 
from outer environment by isolating the inhaled foreign allergens (Al-Muhsen et al., 
2011). In addition, the epithelial also serves as the regulator for both metabolic and 
immunologic functions in the airways (Tagaya and Tamaoki, 2007). Cells in the 
epithelium layer are capable to undergo regeneration, allowing normal cell turnover 
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and restoration of airway and alveolar functions following injury in the lungs 
(Hermans and Bernard, 1999).   
Alteration in the epithelial layer of asthmatic patients including epithelial 
shedding, loss of ciliated cells, goblet cell hyperplasia, and upregulation of growth 
factors, cytokines and chemokines (Al-Muhsen et al., 2011, Shifren et al., 2012).  
Continuous exposure towards allergens and proinflammatory mediators as in 
asthmatic cases put the epithelial cells on stress mode. As transforming growth 
factor-β (TGF-β) gene activated the signalling pathway, the gene induced apoptosis 
of airway epithelial cells which results in the detachment of the epithelial cells 
(Halwani et al., 2011).    
Histologically, epithelial damage and detachment from the basement 
membrane has been frequently reported in various asthma models. Increased level of 
epithelial cells in the bronchoalveolar lavage (BAL) specimens and presence of 
clustered of sloughed epithelial cells (Creola bodies) in the sputum are correlates 
with the airway hyperresponsiveness (AHR) (Jeffery, 2001). The degree of AHR is 
correlates with the degree of epithelial detachment which in turn reflects the severity 
of the disease (Jeffery, 2001, Aoshiba and Nagai, 2004). However, findings from few 
studies did not support this correlation. In a review done by Carroll et al. (1993), it 
was showed the evidence of airways with intact surface epithelium even though  in 
the presence of intense inflammation and other structural changes. This variability is 
likely due to factors such as inherent fragility of the epithelium in asthmatic, 
mechanical stresses imposed during bronchoscopy, and the sampling technique 
(Jeffery, 2001, Shifren et al., 2012).  
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1.3.2 (b) Mucus secreting cells 
Goblet cells and submucosal glands are responsible in secreting mucus into 
airways which functioning in protecting the epithelial surface from injury. In 
response to injury, goblet cells become activated and increased in number. Together, 
a high proportion of goblet cells and submucosal gland enlargement lead to mucus 
hypersecretion into the airway which is a distinct feature of asthma. Previous studies 
have consistently shown the correlation of asthma (regardless of disease severity) 
with goblet cell hyperplasia (Tagaya and Tamaoki, 2007, Shifren et al., 2012). 
Simultaneously, mucus aggravation also contributed by mucous gland hyperthrophy 
which are normally found in the subepithelium (Saetta and Turato, 2001, Tagaya and 
Tamaoki, 2007).   
1.3.2 (c) Reticular basement membrane 
Asthma is also associated with thickening of subepithelial reticular basement 
membrane (RBM). Histologically, the epithelial basement membrane consists of two 
layers namely basal lamina and lamina reticularis. It was reported that thickening of 
basement membrane in asthma took place in reticularis layer (Tagaya and Tamaoki, 
2007). Thickening in this regions occurred due to deposition of collagen type I, III, 
IV, and ECM proteins. This thickening is also known as subepithelial fibrosis 
(Jeffery, 2001, Saetta and Turato, 2001, Tagaya and Tamaoki, 2007).  
1.3.2 (d) Angiogenesis 
 Angiogenesis is a process of proliferation of bronchial vessels (BV) which 
enhance the vascularity of the airways. BV play important role in regulating the 
airway calibre. Increased in vascularity resulted in vascular congestion and later 
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caused swollen of the mucosa. As a result, this accounts for narrowing the airway 
lumen (Fahy et al., 2000, Jeffery, 2001).   
1.3.2 (e) Airway smooth muscle 
Increased in the smooth muscle mass has been considered as the most 
prominent feature in development of asthma. In asthmatics, remodelling of SM 
involved two steps; hyperplasia of myocyte and hypertrophy of myocyte (Jeffery, 
2001, Shifren et al., 2012). Hyperplasia of SM was discovered to occur only in the 
central airways. Whilst, hypertrophy of SM took place in the whole airway tree 
including bronchioles (Tagaya and Tamaoki, 2007). Previous studies showed that 
hyperplasia of SM seem to be dominant over hypertrophy with the numbers of 
myocyte increased two- to three-fold higher than in normal condition (Fahy et al., 
2000). Increased in SM resulted in thickening of the airway wall, narrowing of the 
airway lumen and reduction of the airway calibre in cases of severe asthma (Saetta 
and Turato, 2001, Aoshiba and Nagai, 2004).  
  
10 
 
 
Figure 1.1 Schematic representation of airway remodelling in asthma. (a) the 
structure of normal and healthy airway while (b) represents the structure of asthmatic 
airway. Adapted from “Airway Inflammation and Remodeling in Asthma” by Fahy, 
Corry, and Boushey, 2000, Current Opinion in Pulmonary Medicine, 6(1), p. 16.  
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Figure 1.2 An overview of remodelling that took place in airway structure of asthma. 
Adapted from “Mechanisms of Airway Remodeling in Asthma” by Tagaya and 
Tamaoki, 2007, Allergology International, 56(4), p.332.  
1.3.3  Consequences of airway remodelling in asthma 
An increased in the SM mass together with angiogenesis and subepithelial 
fibrosis contributed to the thickening of the airway wall. Thickened airway wall will 
further narrowing the airway lumen and resulted in significant increase of airway 
resistance, thus limiting the airflow. Increased in the amount of mucus secretion and 
the presence of other inflammatory exudates such as plasma protein in the airway 
lumen resulted in the formation of mucus „plugs‟ in the airways. This will further 
enhance the airflow limitation and hence resulted in airway obstruction (Fahy et al., 
2000, Saetta and Turato, 2001, Shifren et al., 2012). All of these consequences are 
responsible in development of clinical symptoms such as chest tightness, wheezing 
and breathlessness.  
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1.4  Treatments in managing lung disease 
Lung disease such as asthma and COPD needs immediate treatment to relieve 
the symptoms once the attack occurred. Currently there are two types of treatment 
available in managing the disease; conventional drug therapy and alternative therapy. 
1.4.1  Conventional drug therapy 
Pharmacotherapy remains the most common method in managing lung disease. 
This therapy has been developed to prevent and control the disease symptoms, 
reduce the frequency and severity of disease exacerbations and reverse airflow 
obstructions (Dahl, 2006). By custom, drug therapy was categorized either as 
bronchodilators (relaxing the airway SM) or as anti-inflammatory drugs (suppressing 
the airway inflammation) (Fanta, 2009). However, in current practice, these 
medications are now classified based on their roles in managing the disease – either 
as quick relieve or long-term control (Fanta, 2009).  
Short acting β-agonist (SABA) and short acting muscarinic antagonist (SAMA) 
are examples of quick relieve medication. Lists of drugs that grouped under SABA 
type of medications are salbutamol, levalbuterol and meaprotenerol whilst example 
of SAMA is ipratropium. These drugs are effective in rapid reversal of airflow 
obstruction and provide prompt relief upon the breathlessness symptoms (Fanta, 
2009, Parmar and Raines, 2015).  
On the other hand, examples of controller medications  used including inhaled 
corticosteroids (ICS), long acting β-agonist (LABA), long acting muscarinic 
antagonist (LAMA), leukotriene modulators, and anti immunoglobulin-E (IgE) 
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therapy (Fanta, 2009, Parmar and Raines, 2015). Of all these therapy, ICS remains as 
the widely used drug in relieving the asthma attack.   
ICS has been considered as the first line therapy in the management of 
persistent asthma (Dahl, 2006, Patel and Schleimer, 2008). Findings from clinical 
studies shown that ICS has the ability to significantly reduce the airway 
inflammation and AHR, preventing the acute exacerbations, improving lung function 
and decreasing the symptoms severity (Georgitis, 1999, Dahl, 2006). This has been 
the major factor in the widespread usage of ICS as the frontline in asthma 
management which also been approved by both national and international guidelines 
(Dahl, 2006, Patel and Schleimer, 2008). 
Despite of positive outcomes of ICS as reported by Dahl (2006) and Georgitis 
(1999), there were also controversies about the role of corticosteroids in restoring the 
airway structure. As mentioned earlier, asthma is featured by alteration in the 
structure of epithelial which includes epithelial damage. Some in vitro studies 
concluded that corticosteroids could increase the apoptosis of epithelial cells which 
in the case if asthma, this could further contributed to chronic epithelial damage 
(Dorscheid et al., 2001, Mauad et al., 2007). On contrary, in a retrospective biopsy 
study, prolong treatment of ICS (10 years) did decreased the inflammation and 
partially improved the epithelial damage (Lundgren et al., 1988).  
It is important to remember that ICS which was developed by chemical 
constituents also possess side effects to the human beings which are categorized into 
local side effect and systemic side effect. Examples of local side effects are 
oropharyngeal candidiasis, dysphonia, reflex cough, bronchospasm and pharyngitis 
(Dahl, 2006). Local side effects are mostly contributed by deposition of 
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corticosteroids  in the oropharyngeal cavity and usually the effects are dose 
dependant (Patel and Schleimer, 2008).  
Systemic side effects are contributed by absorption of corticosteroids through 
lungs and gastrointestinal tract (GIT). Most of the currently available ICS have been 
designed to undergo first-pass metabolic inactivation in the liver following 
absorption from the GIT before reaching the systemic circulation (Wood and Barnes, 
1995, Fanta, 2009). Nevertheless, prolong administration of ICS and high dose 
therapy can cause adverse side effects such as skin thinning and skin bruising, 
cataracts, elevated intraocular pressure, accelerated loss of bone mass, bone fractures 
and osteoporosis (Dahl, 2006, Fanta, 2009).  
Due to adverse side effects possess by conventional drug therapy especially 
ICS, this highlights the need to find alternative therapy with less side effects 
preferably nature-based therapy.     
1.4.2  Alternative treatment    
Alternative treatments from natural resources could provide promising results 
in finding solutions to replace conventional therapy and thus minimizing the risk of 
gaining unwanted secondary effects from the treatment itself. For this purpose, 
various studies have been carried out in examining the potential ability of various 
natural herbs in reducing and managing the disease symptoms. Several studies 
concludes that extracts from Nigella sativa oil (El Gazzar et al., 2006, Balaha et al., 
2012), Mimosa pudica plant (Yang et al., 2011b), Lagerstroemia indica plant (Yang 
et al., 2011a), Duchesnea chrysantha herb plant (Yang et al., 2008), Bambusae caulis 
in Taeniam (family of bamboo) (Ra et al., 2010) and skullcapflavone II, a flavanoid 
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isolated from Scutellabaria baicalensis herb plant (Jang et al., 2012) have the ability 
to ameliorate ovalbumin (OVA)-induced airway inflammation in animal model of 
asthma. This include reducing the eosinophils infiltration, inhibiting the goblet cell 
hyperplasia, improving the lung functions and suppressing the level of T-helper type 
(Th2) cytokines and thus restoring the balance of Th1/Th2 cytokines.  
1.5  Honey – the hidden forest gold    
Honey is a natural product produced by honeybees from nectars. By nature, 
honey is a viscous substance with pleasant taste as it is composed by a complex 
mixture of sugars. The composition and physicochemical properties of honey are 
variable according to its geographical origin, floral source, environmental and 
seasonal conditions processing techniques (Erejuwa et al., 2012a). Honey can be 
grouped into monofloral or multifloral depending on its botanical nectar source. 
Monofloral honey is produced by nectars collected from one flower species whilst 
multifloral honey is produced by nectars collected from multiple flower species 
(Erejuwa et al., 2012a). 
Honey has been scientifically reported to have both medicinal and nutritional 
values based on its various biological properties including as anti-inflammatory, 
antioxidant, anti-bacterial, anti-diabetic, anti-microbial and wound healing (Ahmed 
and Othman, 2013). Manuka honey, a monofloral honey originated from New 
Zealand, has been extensively studied and is well known for various medicinal 
properties and its antioxidants, anti-bacterial, and anti-fungal properties has been 
well published. In fact, Manuka honey has been setup as the „gold standard‟ for 
comparison studies with other types of honey (Ahmed and Othman, 2013).  
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Malaysia is well known for its varieties of honey such as Tualang honey, 
Gelam honey, Kelulut honey, and Acacia honey. Among all types of Malaysian 
honey, Tualang (Koompassia Excelsa) honey (TH) recently gained attention from the 
researchers to further explore its potential benefits.     
TH is a multifloral honey produced by the rock bee (Apis dorsata). TH gained 
its name as the honey is collected from hives build up in the branches of Koompassia 
excelsa plant or locally known as Tualang tree (Ahmed and Othman, 2013). On the 
other hand, Gelam honey is also produced by Apis dorsata bees in which nectar and 
pollens are collected from the plant Melaleuca cajuputi Powell or locally known as 
Gelam tree (Khalil et al., 2011). Acacia honey gained its name as the nectar is 
collected by Apis mellifera bees from the Acacia mangium trees (Moniruzzaman et 
al., 2013).  
1.5.1 Composition and physicochemical properties of Tualang honey 
In general, honey is composed of mixture of sugars mainly fructose (38%) and 
glucose (31%), and contains more than 180 components phenolic acids and 
flavonoids, enzymes, vitamins, minerals and proteins (Viuda‐Martos et al., 2008, 
Ahmed and Othman, 2013). TH has dark brown appearance with pH ranging from 
3.55 to 4.00 and a specific gravity of 1.335 (Ghazali, 2009). The low pH of TH is 
similar with Manuka honey but more acidic compared to both Kelulut and Gelam 
honey, thus make it effective as antibacterial and antimicrobial against several 
pathogenic microorganisms (Tan et al., 2009a, Ahmed and Othman, 2013).   
Analysis of volatile compounds in TH using gas chromatography mass 
spectrometry revealed that TH is primarily composed by 58.54% of hydrocarbons, 
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11.26% of ketones, aldehydes (10.26%), acids and alcohol (6.76%), and organic 
acids (1.44%). Other constituents including terpenes and furans (Nurul et al., 2013).   
A total of six phenolic acids have been discovered in TH which are gallic acid, 
syringic acid, benzoic acid, transcinnamic acid, p-coumaric acid and caffeic acid. TH 
also consists of five flavonoids including catechin, kaempferol, naringenin, luteolin 
and apigenin (Khalil et al., 2010, Khalil et al., 2011, Ahmed and Othman, 2013).   
Phenolic compounds has been reported to exhibit properties such as antioxidants, 
anti-inflammatory, anti-carcinogenic and others (Kassim et al., 2010). 
1.5.2  Medicinal benefits of Tualang honey 
Honey has been used to cure various kinds of ailments in both traditional and 
modern medicine. To date, various studies have been conducted in both in vivo and 
in vitro to investigate the biological properties of honey especially TH. TH is well 
known to possess properties such as anti-inflammatory (Bashkaran et al., 2011), anti-
bacterial (Tan et al., 2009a, Tan et al., 2009b), anti-diabetic (Erejuwa et al., 2012a), 
anti-cancer (Ghashm et al., 2010), anti-hypertensive (Erejuwa et al., 2012b) and 
antioxidant (Ahmed and Othman, 2013).  
It has been well documented that TH can serve as alternative treatments in the 
wound healing. Both clinical and pre-clinical studies show the promising results of 
application of TH on wound healing. In a clinical study done by Imran and her 
friends, application of TH-based hydrogel improved the wound healing in the 
patients of split-skin graft (Imran et al., 2011). This is further supported by findings 
from other clinical study which reported the ability of TH dressing in healing the 
diabetic foot wounds (Nawfar et al., 2011), incision wound (Zaharil et al., 2011), and 
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burn wounds (Khoo et al., 2010, Sukur et al., 2011). In general, honey improves 
wound healing by abating oedema, inflammation, exudation and promoting the 
growth of epithelial cells and fibroblast (Ahmed and Othman, 2013). The ability of 
TH in wound healing is attributed by its antibacterial and antioxidant properties (Tan 
et al., 2009a, Nasir et al., 2010). High content of phenolics and flavonoids in TH 
attributed to its antioxidant activities which is higher compared to other local and 
commercially available honey (Khalil et al., 2011). 
Although honey has high level of fructose and glucose, however, it can be used 
in managing the diabetes mellitus (DM). In an in vivo study, combination of TH with 
metformin or glibenclamide (common drug to treat DM) significantly lowered the 
blood glucose level compared to the metformin or glibenclamide alone. Hence, this 
proves the ability of TH in combination with hypoglycaemic agents to improve the 
glycaemic control in streptozotocin-induced diabetic rats (Erejuwa et al., 2011).  
1.5.3  Honey as treatment for respiratory diseases 
The scientific findings that reported the potential use of honey in treating 
respiratory-related diseases are very limited. So far, there are three published works 
that studied the effect of honey in treating cough and upper acute asthma.      
Cough is usually associated with upper respiratory infections. Honey 
supplementation has been widely used to treat cough since ancient times. Previous 
study supports the goodness of buckwheat honey in comparison to dextromethorphan 
as treatment in children with nocturnal cough and sleep difficulty due to upper 
respiratory tract infection (Paul et al., 2007). A preliminary study to assess the 
benefit of TH in reducing acute respiratory symptoms such as cough, rhinitis and 
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sore throats was conducted in 2007 (Sulaiman et al., 2011). Studied population was 
Malaysian hajj pilgrims who were commonly associated with these symptoms while 
performing hajj. Oral consumption of honey twice daily did aid in alleviating the 
respiratory symptoms among pilgrims. Due to a small sample size (n=56) and a short 
study timeline (42 days), thus, the significant effect of TH in reducing respiratory 
symptoms could not be concluded (Sulaiman et al., 2011).     
Other study done by Maksoud and Rahman (2007), reported honey inhalation 
was effective in treating acute bronchial asthma in paediatric patients. This is the 
only study that focused on the effect of honey in treating lung injury. However, the 
mechanism of action of honey as lung injury treatment remains unclear. The authors 
did not mention the effect of honey on pathogenesis of lung injury at both cellular 
and molecular level. In fact, none of the documentation did report the potential use of 
TH in lung injury management so far. This later became the subject of interest in this 
current study.  
1.6  Rabbits as animal model of chronic lung injury 
As mentioned earlier, chronic lung injury contributed to thousands of death 
annually worldwide. Thus, development of prevention strategies and new treatment 
methods for the disease is a must. Therefore, a biological model is needed in order to 
understand the mechanism and development of a disease at both cellular and 
molecular level. Animal model seem to be a perfect experimental model as it 
provides an experimental setting that allow the researchers to study the interaction 
between immune system and the functioning respiratory system (Kamaruzaman et 
al., 2013).   
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An ideal animal model of chronic lung injury must have the ability to 
reproduce both the anatomical and physiology features resembling to the human 
chronic lung disease. This includes IgE-mediated sensitivity to antigens, increase 
airway resistance, acute bronchoconstriction, chronic airway inflammation, 
eosinophilic infiltration, mucus hypersecretion, Th2 cytokines production, airway 
wall remodelling and smooth muscle hyperplasia (Keir and Page, 2008). Choosing an 
ideal animal model for chronic lung disease is very decisive and need critical 
judgement. It is important to choose animals that have similarity with the physiology 
and organ size of human lungs which can only be offered by large-sized animals 
(Zosky and Sly, 2007). Measurement of lung functions in small-sized animals would 
seem to be technically challenging. Besides that, the anatomical structure of the 
lungs also an important criterion to be considered in choosing the right animal 
model.     
Rabbit shared similarities with human airways and is phylogenetically closer to 
human than any other rodents. Both rabbit and human have abundant submucosal 
gland and mucous secreting goblet cells in the upper airways in contrast to mice 
(Koehler et al., 2005). This provides an advantage in the disease development and 
research as asthma is also associated with goblet cell hyperplasia. Moreover, the 
model itself possess lungs that are large enough to study lung mechanics 
(Kamaruzaman et al., 2013). Thus, this provides rabbit as a useful species to study 
lung biology in order to understand the human lungs conditions. This is supported by 
earlier work in rabbits as model in investigating the effectiveness of lung reduction 
surgery in treatment of emphysema and COPD (Keir and Page, 2008). The treatment 
is a success and currently being used at the clinical setting. It similarities with human 
lungs provides rabbits as useful tool as models for studying asthma.    
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1.7  Allergen used in inducing chronic lung injury 
In any animal model of allergic disease, it is important to develop the disease 
which having similar immunological and pathophysiological characteristic as in 
human. This can be achieved by the use of allergen such as ovalbumin (OVA), house 
dust mite (HDM) and Aspergillus fumigatus.    
1.7.1  Ovalbumin 
OVA is the most commonly allergen used in inducing allergic disease in 
animal model. OVA is usually being introduced into the model system by two steps; 
sensitization and repeated exposure by means of inhalation. Sensitization of OVA is 
usually coupled with Th2-skewing adjuvant such as aluminum hydroxide (alum) 
with the aim to prime the allergic airway inflammation (Conrad et al., 2009). Both 
OVA and alum are introduced into the animal model by injection into the peritoneal 
cavity. Repeated injections of OVA together with alum is reported to induce strong, 
sustained sensitization with a preferential Th2-type immune response and production 
of allergen-specific IgE and immunoglobulin G1 (IgG1) which resembling the 
allergic sensitization in atopic individuals (Hamelmann and Gelfand, 1999). 
Following sensitization, animals models are further exposed to repeated inhalation of 
OVA which later develop AHR and recruitment of inflammatory cells such as 
eosinophils, T-cells and neutrophils into airway tissue (Piavaux et al., 2007). 
1.7.2  House dust mite 
HDM is an aeroallergen and one of the examples is Dermatophagoides 
pteronyssinus. HDM is quite dangerous compared to OVA as exposure to HDM by 
any genetic susceptible individuals can cause symptoms from as mild as atopic 
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dermatitis to bronchial asthma (Piavaux et al., 2007). Unlike OVA which require the 
presence of adjuvant, intranasal exposure towards HDM alone can generate both 
acute and chronic airway inflammation, induce the development of AHR and 
increase the Th2-type inflammatory cell response (Cates et al., 2004, Johnson et al., 
2004).  
1.7.3  Aspergillus fumigatus 
A.fumigatus is an allergic fungi which are widely distributed in the 
environment. Sensitization by A.fumigatus causing elevated levels of IgE and 
eosinophils, enhances the Th2 cytokines, development of AHR and profound airway 
remodelling (Piavaux et al., 2007). The crude extract of A.fumigatus is highly 
antigenic and it contains active substances such as ribotoxins and protease. 
Sensitization with A.fumigatus do not required adjuvant as protease itself serves as 
adjuvant by inducing epithelial damage in the airways and allowing normally 
excluded antigens to bypass the mucosal barrier (Tomee et al., 1997).  
 
23 
 
1.8 Rational of the study 
The establishment of aerosol delivery of honey using nebulizer was aimed to 
provide an alternative option for treatment of chronic lung injury by using nature-
based product. With the increase in the awareness of side effects offered by the 
conventional drug therapy, it is hoped that honey-based medication could be a 
potential as a complementary and alternative medicine for the management of 
chronic lung injury patients.  
1.9 Objectives of the study 
1.9.1  General objective 
The general objective of this study was to study the effect of aerosolised- 
honey on airway epithelium repair and regeneration following ovalbumin-induced 
chronic lung injury in rabbit model.  
1.9.2 Specific objectives 
This study was aimed to address the following objectives:  
1. To develop rabbit as an in vivo model of chronic lung injury (i.e. that mimic 
human condition of asthma) by repetitive exposure to OVA. 
2. To determine the effective dose of honey administration to the chronic airway 
using aerosol-based inhalation technique. 
3. To study the effect of aerosolised-honey on pathophysiological changes of 
chronic-induced lung airway tissue (i.e. airway epithelium, mucosal region, 
submucosal region, goblet cells) using established histological staining 
techniques. 
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1.10 Study hypothesis 
1. Inhalation of honey can reduce the inflammatory responses of the airway. 
2. Aerosolisation is feasible and effective route of delivery of honey for 
treatment of chronic lung diseases.  
